El-Atoum Mohammad, Gailor Mary E, Segal Brahm H, Bonnewell John P, Almyroudis Nikolaos G
Department of Internal Medicine, University at Buffalo-The State University of New York, Buffalo, New York, USA.
Division of Infectious Diseases, Department of Internal Medicine, Roswell Park Comprehensive Cancer Center and Jacobs School of Medicine and Biomedical Sciences, State University of New York, Buffalo, New York, USA.
Open Forum Infect Dis. 2024 Oct 11;11(10):ofae580. doi: 10.1093/ofid/ofae580. eCollection 2024 Oct.
are mucous membrane commensals that infrequently cause invasive disease. Our goal was to define species prevalence, the predominant disease site and risk factors for actinomycosis.
We retrospectively reviewed patients with growth of species from cultures in a single-cancer center from July 2007 to June 2020. Proven invasive actinomycosis was defined as the presence of compatible clinical syndrome and radiographic findings with histopathological confirmation or culture from a normally sterile site. Probable invasive actinomycosis was defined based on the same criteria but without histologic confirmation. Contaminants were defined as culture growth in the absence of clinical or radiological findings consistent with disease. Speciation of was performed by the bioMerieux VITEK 2 anaerobic and coryneform identification card.
Of 235 patients, 179 (76.2%) had malignancy. Among 90 (38.3%) patients with invasive actinomycosis, was isolated in 32 (35.6%), followed by in 20 (22.2%), and in 17 (18.9%). Among 145 (61.7%) colonized patients, was isolated in 67 (46.2%), followed by in 27 (18.6%). Abdominopelvic infection was the most common site for invasive actinomycosis documented in 54 patients (60.0%) followed by orocervicofacial in 14 (15.6%) and thoracic in 10 (11.1%).
and were the most frequently isolated species causing invasive actinomycosis, and and among colonizers. Abdominopelvic represented the most frequent site for invasive disease. Further studies are needed to investigate the epidemiology of species in this population.
[具体放线菌属名称]是黏膜共生菌，很少引起侵袭性疾病。我们的目标是确定[具体放线菌属名称]的物种流行情况、主要疾病部位及放线菌病的危险因素。
我们回顾性分析了2007年7月至2020年6月在单一癌症中心培养出[具体放线菌属名称]的患者。确诊的侵袭性放线菌病定义为存在符合临床综合征和影像学表现，并经组织病理学证实或从正常无菌部位培养出[具体放线菌属名称]。可能的侵袭性放线菌病根据相同标准定义，但未经组织学证实。污染物定义为在无符合疾病的临床或放射学表现情况下的培养生长。[具体放线菌属名称]的菌种鉴定通过生物梅里埃VITEK 2厌氧和棒状杆菌鉴定卡进行。
235例患者中，179例（76.2%）患有恶性肿瘤。在90例（38.3%）侵袭性放线菌病患者中，[具体放线菌属名称1]分离出32例（35.6%），其次是[具体放线菌属名称2]20例（22.2%），[具体放线菌属名称3]17例（18.9%）。在145例（61.7%）定植患者中，[具体放线菌属名称1]分离出67例（46.2%），其次是[具体放线菌属名称2]27例（18.6%）。腹盆腔感染是侵袭性放线菌病最常见的部位，54例（60.0%）有记录，其次是口颈面部14例（15.6%）和胸部10例（11.1%）。
[具体放线菌属名称1]和[具体放线菌属名称2]是引起侵袭性放线菌病最常分离出的菌种，[具体放线菌属名称1]和[具体放线菌属名称2]是定植菌中最常分离出的。腹盆腔是侵袭性疾病最常见的部位。需要进一步研究调查该人群中[具体放线菌属名称]菌种的流行病学情况。
